menu
    • menu
    PHARMACOMPASS
    PHARMACOMPASS

    Grow Your Pharma Business Digitally
    X
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Relief Announces Six-Month Stability Data on a New Formulation of RLF-100

    ACCESSWIRE

    Relief Therapeutics Announces Promising Initial Stability Data on RLF-100(R)

    ACCESSWIRE

    Déjà vu: FDA rejects NRx filing for emergency use in COVID-19

    FIERCEBIOTECH

    NRx Pharma Provides Update on BTD Request for ZYESAMI

    PRNEWSWIRE

    NRx to halt analysis of Zyesami for critical Covid-19 due to futility

    CLINICALTRIALSARENA

    NRx tanks as peptide fails NIH trial in severe COVID-19 patients

    FIERCEBIOTECH

    NRx Pharma Files New Breakthrough Therapy Designation Request for ZYESAMI®

    PRNEWSWIRE

    I-SPY COVID Trial Suggests No Benefit with Addition of Nebulized ZYESAMI

    PRNEWSWIRE

    NRx Pharma Expand ZYESAMI US Access and Right to Try Programs

    GLOBENEWSWIRE

    NRx seeks breakthrough therapy designation for Covid-19 treatment

    PHARMACEUTICAL-TECHNOLOGY

    NRx provides encouraging safety data of Zyesami in Covid-19 trial

    CLINICALTRIALSARENA

    NRx Announces New, Favorable Safety Report for ZYESAMI® (aviptadil)

    GLOBENEWSWIRE

    NRx Pharmaceuticals Identifies Significantly Higher Likelihood

    GLOBENEWSWIRE

    NRx Pharmaceuticals Receives FDA Review of ZYESAMI Manufacturing Information

    GLOBENEWSWIRE

    US Food and Drug Administration Declines Emergency Use Authorization ZYESAMI®

    PRNEWSWIRE

    NRx Pharmaceuticals Announces Favorable, New Safety Report for ZYESAMI®

    PRNEWSWIRE

    NRx Pharma up 35% on supply arrangement for Zyesami

    SEEKINGALPHA

    NRx Pharma Announces Progress on Worldwide Commercial Scale DevP of ZYESAMI™

    PRNEWSWIRE

    Study finds NRx’s Zyesami boosts survival in comorbid Covid-19 patients

    CLINICALTRIALSARENA

    NRx Pharma Announces Positive Data for ZYESAMI (aviptadil)

    PRNEWSWIRE

    Relief Therapeutics Provides Update on Regulatory Interactions in the UK

    PRESS RELEASE

    NRx Pharma provides positive safety update on Zyesami in Phase 3 study

    PHARMABIZ

    NRx Starts Emergency Use Training and Extension of Phase 2/3 Inhaled ZYESAM

    PR NEWSWIRE

    NRx Starts Emergency Use Training and Extension of Phase 2/3 Inhaled ZYESAM

    PR NEWSWIRE

    Biophore applies for DCGI approval for EU of Aviptadil to treat COVID-19

    EXPRESS PHARMA

    Relief Confirms Release of 60-Day Findings from Ph 2b/3 Clinical Trial RLF-100™

    BIOSPACE

    NeuroRx Announces that ZYESAMI™ (Aviptadil) has Successfully Demonstrated 10

    PRNEWSWIRE

    NeuroRx’s Zyesami accelerates recovery in Covid-19 trial

    CLINICALTRIALSARENA

    NeuroRx Announces that ZYESAMI™ (Aviptadil) has Successfully Demonstrated 10-Day

    PRNEWSWIRE

    NeuroRx reports Initial Phase 2b/3 Study Results Benefit of ZYESAMI™

    PRNEWSWIRE

    NeuroRx Initiates Ph2/3 Study of Inhaled ZYESAMI™ for COVID-19 UCI Health

    PRNEWSWIRE

    NeuroRx & Relief announce topline efficacy data from patients treated RLF-100™

    PRNEWSWIRE

    Relief Therapeutics announces supply deals while awaiting COVID-19 trial data

    REUTERS

    Relief Announces Capital Increase from its Final Tranche

    BIOSPACE

    NeuroRx requests emergency use of RLF-100 in COVID-19

    SEEKING ALPHA

    FDA Grants Inhaled Use IND for RLF-100 (Aviptadil) to Treat Patients Moderate

    BUSINESSWIRE

    New drug RLF-100 shows dramatic recovery in COVID-19 patients suffering

    INDIATIMES

    Relief ’ aviptadil gets US FDA expanded access protocol respiratory failure

    PHARMABIZ

    US FDA grants fast track status to Aviptadil to treat respiratory distress

    PHARMABIZ

    FDA grants fast track status to NeuroRx’s Covid-19 drug candidate

    PHARMACEUTICAL-TECHNOLOGY

    Relief Therapeutics & NeuroRx Expand Clinical Trial of RLF-100 to All Patients

    GLOBENEWSWIRE

    Relief Therapeutics Announces Filing of IND for Ph2/3 Trial of Inhaled RLF-100

    GLOBENEWSWIRE

    Relief Therapeutics studies Aviptadil for Covid-19-related ARDS

    CLINICALTRIALSARENA

    RELIEF THERAPEUTICS & NeuroRx File FDA IND for Aviptadil to Treat COVID-19

    PRNEWSWIRE

    RELIEF THERAPEUTICS & NeuroRx File FDA IND for Aviptadil to Treat COVID-19

    PRNEWSWIRE

    RELIEF THERAPEUTICS Holding SA Announces an Out-Licensing Agreement with H&H Group

    BUSINESSWIRE

    Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.